Compare ALLE & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLE | FMS |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | Ireland | Germany |
| Employees | N/A | 108165 |
| Industry | Diversified Commercial Services | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 12.5B |
| IPO Year | 2013 | N/A |
| Metric | ALLE | FMS |
|---|---|---|
| Price | $136.85 | $24.10 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 8 | 2 |
| Target Price | ★ $167.13 | $30.00 |
| AVG Volume (30 Days) | ★ 1.2M | 559.5K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | 1.60% | ★ 2.57% |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $4.58 | $3.83 |
| P/E Ratio | $87.92 | ★ $15.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $125.00 | $20.02 |
| 52 Week High | $183.11 | $27.64 |
| Indicator | ALLE | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 60.46 |
| Support Level | $132.03 | $22.47 |
| Resistance Level | $148.87 | $24.71 |
| Average True Range (ATR) | 3.50 | 0.33 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 47.55 | 80.78 |
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.